United States

Manojna Maddipatla

J&J warns of hit from generic drugs in third quarter, shares fall

Jul 16 2019

Johnson & Johnson on Tuesday boosted its 2019 sales forecast amid robust demand for its cancer drugs, but warned that competition from generic and copycat drugs could impact its third-quarter results, sending shares down 1.4% in noon trading.

Intra-Cellular drug fails bipolar depression study; shares fall 14%

Jul 08 2019

Intra-Cellular Therapies Inc said on Monday its lead drug failed to meet the main goal of a late-stage study in patients with major depressive episodes associated with bipolar disorder.

Karyopharm Therapeutics prices blood cancer treatment after FDA approval

Jul 03 2019

Karyopharm Therapeutics Inc on Wednesday set a list-price for its blood cancer treatment Xpovio at $22,000 per month, following accelerated approval from the U.S. Food and Drug Administration.

CORRECTED-UPDATE 1-U.S. FDA approves Karyopharm Therapeutics' blood cancer drug

Jul 03 2019

July 3 The U.S. Food and Drug Administration on Wednesday approved Karyopharm Therapeutics Inc's treatment for multiple myeloma, a type of blood cancer.

VBI's shares plunge after hep B vaccine fails secondary goal in late-stage trial

Jun 17 2019

VBI Vaccines Inc said on Monday a late-stage study was unsuccessful in showing two doses of its hepatitis B vaccine were as effective as three doses of an older vaccine from GlaxoSmithKline, sending its shares plunging 66%.

Allergan's Vraylar wins FDA approval for bipolar depression

May 28 2019

Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

May 14 2019

Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

Allergan CEO says company is urgently looking at all options to boost share price

May 07 2019

Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

Biogen dips as strategy post Alzheimer's setback fails to impress

Apr 24 2019

Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.

World News